



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the use of Bortezomib in Multiple Myeloma (MM)  
Capital District Health Authority/*Cancer Care Nova Scotia***

**Approved Use:**

**Bortezomib:** As a **single agent** in the second or third line setting of refractory or relapsed MM. In situations where patients have relapsed or demonstrated refractory disease following first or second line options such as autologous stem cell transplantation, alkylating-based (i.e. melphalan and prednisone) or multi-agent chemotherapy (i.e. VAD – vincristine, adriamycin, dexamethasone), and choose to receive additional therapy, bortezomib is a reasonable option.

- This policy recommendation represents a **new guideline document** and an **addition** to the list of restricted drugs for the use of bortezomib in MM.